Stereotactic Body Radiation Therapy for Patients With Sacral Chordoma Who Previously Received Carbon Ion Therapy
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
SEARCH · Search NASA
Results for “carbon therapy”
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
A TOPAS model for lens-based proton radiography
Abstract Objective. Proton Radiography can be used in conjunction with proton therapy for patient positioning, real-time estimates of stopping power, and adaptive therapy in regions with motion. The modeling capability shown here can be used to evaluate lens-based radiography as an instantaneous proton-based radiographic technique. The utilization of user-friendly Monte Carlo program TOPAS enables collaborators and other users to easily conduct medical- and therapy- based simulations of the Los Alamos Neutron Science Center (LANSCE). The resulting transport model is an open-source Monte Carlo package for simulations of proton and heavy ion therapy treatments and concurrent particle imaging. Approach. The four-quadrupole, magnetic lens system of the 800-MeV proton beamline at LANSCE is modeled in TOPAS. Several imaging and contrast objects were modelled to assess transmission at energies from 230–930 MeV and different levels of particle collimation. At different proton energies, the strength of the magnetic field was scaled according to βγ, the inverse product of particle relativistic velocity and particle momentum. Main results. Materials with high atomic number, Z, (gold, gallium, bone-equivalent) generated more contrast than materials with low-Z (water, lung-equivalent, adipose-equivalent). A 5-mrad collimator was beneficial for tissue-to-contrast agent contrast, while a 10-mrad collimator was best to distinguish between different high-Z materials. Assessment with a step-wedge phantom showed water-equivalent path length did not scale directly according to predicted values but could be mapped more accurately with calibration. Poor image quality was observed at low energies (230 MeV), but improved as proton energy increased, with sub-mm resolution at 630 MeV. Significance. Proton radiography becomes viable for shallow bone structures at 330 MeV, and for deeper structures at 630 MeV. Visibility improves with use of high-Z contrast agents. This modality may be particularly viable at carbon therapy centers with accelerators capable of delivering high energy protons and could be performed with carbon therapy.
60 APPLIED LIFE SCIENCES↗
Th Balance–Related Host Genetic Background Affects the Therapeutic Effects of Combining Carbon-Ion Radiation Therapy With Dendritic Cell Immunotherapy
The goal of this study is to clarify the underlying mechanisms of metastasis suppression by carbon-ion radiotherapy combined with immature dendritic cell immunotherapy (CiDC), which was shown previously to suppress pulmonary metastasis in an NR-S1–bearing C3H/He mouse model.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Carbon Ion Radiation Therapy: One Decade of Research and Clinical Experience at Heidelberg Ion Beam Therapy Center
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Results of a Geant4 benchmarking study for bio‐medical applications, performed with the G4‐Med system
Geant4, a Monte Carlo Simulation Toolkit extensively used in bio-medical physics, is in continuous evolution to include newest research findings to improve its accuracy and to respond to the evolving needs of a very diverse user community. In 2014, the G4-Med benchmarking system was born from the effort of the Geant4 Medical Simulation Benchmarking Group, to benchmark and monitor the evolution of Geant4 for medical physics applications. The G4-Med system was first described in our Medical Physics Special Report published in 2021. Results of the tests were reported for Geant4 10.5. Purpose In this work, we describe the evolution of the G4-Med benchmarking system. Methods The G4-Med benchmarking suite currently includes 23 tests, which benchmark Geant4 from the calculation of basic physical quantities to the simulation of more clinically relevant set-ups. New tests concern the benchmarking of Geant4-DNA physics and chemistry components for regression testing purposes, dosimetry for brachytherapy with a 125 I source, dosimetry for external x-ray and electron FLASH radiotherapy, experimental microdosimetry for proton therapy, and in vivo PET for carbon and oxygen beams. Regression testing has been performed between Geant4 10.5 and 11.1. Finally, a simple Geant4 simulation has been developed and used to compare Geant4 EM physics constructors and physics lists in terms of execution times. Results In summary, our EM tests show that the parameters of the multiple scattering in the Geant4 EM constructor G4EmStandardPhysics_option3 in Geant4 11.1, while improving the modeling of the electron backscattering in high atomic number targets, are not adequate for dosimetry for clinical x-ray and electron beams. Therefore, these parameters have been reverted back to those of Geant4 10.5 in Geant4 11.2.1. The x-ray radiotherapy test shows significant differences in the modeling of the bremsstrahlung process, especially between G4EmPenelopePhysics and the other constructors under study (G4EmLivermorePhysics, G4EmStandardPhysics_option3, and G4EmStandardPhysics_option4). These differences will be studied in an in-depth investigation within our Group. Improvement in Geant4 11.1 has been observed for the modeling of the proton and carbon ion Bragg peak with energies of clinical interest, thanks to the adoption of ICRU90 to calculate the low energy proton stopping powers in water and of the Linhard–Sorensen ion model, available in Geant4 since version 11.0. Nuclear fragmentation tests of interest for carbon ion therapy show differences between Geant4 10.5 and 11.1 in terms of fragment yields. In particular, a higher production of boron fragments is observed with Geant4 11.1, leading to a better agreement with reference data for this fragment. Conclusions Based on the overall results of our tests, we recommend to use G4EmStandardPhysics_option4 as EM constructor and QGSP_BIC_HP with G4EmStandardPhysics_option4, for hadrontherapy applications. The Geant4-DNA physics lists report differences in modeling electron interactions in water, however, the tests have a pure regression testing purpose so no recommendation can be formulated.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Differential Immune Modulation With Carbon-Ion Versus Photon Therapy
Radiation therapy (RT) modulates the immune characteristics of the tumor microenvironment (TME). It is not known whether these effects are dependent on the type of RT used.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Test Results of a High-Gradient 2.856-GHz Negative Harmonic Accelerating Waveguide
We report the high-gradient tests results of a novel traveling wave accelerating structure for β=0.3 based on a novel approach of operating at the first negative spatial harmonic. Accelerating gradients of 50 MV/m and peak electric fields of 160 MV/m were achieved in a single structure consisting of 15 coupled cells during tests at the advanced photon source. This work was performed by RadiaBeam, in collaboration with the Argonne National Laboratory, as a part of a Research and Development Program for the development of an ultrahigh-gradient linear accelerator, the Advanced Compact Carbon Ion Linac, for hadron therapy.
42 ENGINEERING↗
Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX
Selective antibody targeted delivery of α particle emitting actinium-225 to tumors has significant therapeutic potential. This work highlights the design and synthesis of a new bifunctional macrocyclic diazacrown ether chelator, H 2 MacropaSqOEt, that can be conjugated to antibodies and forms stable complexes with actinium-225. The macrocyclic diazacrown ether chelator incorporates a linker comprised of a short polyethylene glycol fragment and a squaramide ester that allows selective reaction with lysine residues on antibodies to form stable vinylogous amide linkages. This new H 2 MacropaSqOEt chelator was used to modify a monoclonal antibody, girentuximab (hG250), that binds to carbonic anhydrase IX, an enzyme that is overexpressed on the surface of cancers such as clear cell renal cell carcinoma. This new antibody conjugate (H 2 MacropaSq-hG250) had an average chelator to antibody ratio of 4 : 1 and retained high affinity for carbonic anhydrase IX. H 2 MacropaSq-hG250 was radiolabeled quantitatively with [ 225 Ac]Ac III within one minute at room temperature with micromolar concentrations of antibody and the radioactive complex is stable in human serum for >7 days. Evaluation of [ 225 Ac]Ac(MacropaSq-hG250) in a mouse xenograft model, that overexpresses carbonic anhydrase IX, demonstrated a highly significant therapeutic response. It is likely that H 2 MacropaSqOEt could be used to modify other antibodies providing a readily adaptable platform for other actinium-225 based therapeutics.
37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors
The combination of radiation therapy and immunotherapy is recognized as a very promising strategy for metastatic cancer treatment. The purpose of this work is to compare the effectiveness of x-ray and high-energy carbon ion therapy in combination with checkpoint inhibitors in a murine model.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
On the perturbation effect and LET dependence of beam quality correction factors in carbon ion beams
Background: In a recent study, we reported beam quality correction factors, f Q , in carbon ion beams using Monte Carlo (MC) methods for a cylindrical and a parallel-plate ionization chamber (IC). A non-negligible perturbation effect was observed; however, the magnitude of the perturbation correction due to the specific IC subcomponents was not included. Furthermore, the stopping power data presented in the International Commission on Radiation Units and Measurements (ICRU) report 73 were used, whereas the latest stopping power data have been reported in the ICRU report 90. Purpose: The aim of this study was to extend our previous work by computing f Q correction factors using the ICRU 90 stopping power data and by reporting IC-specific perturbation correction factors. Possible energy or linear energy transfer (LET) dependence of the f Q correction factor was investigated by simulating both pristine beams and spread-out Bragg peaks (SOBPs). Methods: The TOol for PArticle Simulation (TOPAS)/GEANT4 MC code was used in this study. A 30 × 30 × 50 cm 3 water phantom was simulated with a uniform 10 × 10 cm 2 parallel beam incident on the surface. A Farmer-type cylindrical IC (Exradin A12) and two parallel-plate ICs (Exradin P11 and A11) were simulated in TOPAS using the manufacturer-provided geometrical drawings. The f Q correction factor was calculated in pristine carbon ion beams in the 150–450 MeV/u energy range at 2 cm depth and in the middle of the flat region of four SOBPs. The k Q correction factor was calculated by simulating the f Qo correction factor in a 60 Co beam at 5 cm depth. The perturbation correction factors due to the presence of the individual IC subcomponents, such as the displacement effect in the air cavity, collecting electrode, chamber wall, and chamber stem, were calculated at 2 cm depth for monoenergetic beams only. Additionally, the mean dose-averaged and track-averaged LET was calculated at the depths at which the f Q was calculated. Results: The ICRU 90 f Q correction factors were reported. The p dis correction factor was found to be significant for the cylindrical IC with magnitudes up to 1.70%. The individual perturbation corrections for the parallel-plate ICs were <1.0% except for the A11 p cel correction at the lowest energy. The f Q correction for the P11 IC exhibited an energy dependence of >1.00% and displayed differences up to 0.87% between pristine beams and SOBPs. Conversely, the f Q for A11 and A12 displayed a minimal energy dependence of <0.50%. The energy dependence was found to manifest in the LET dependence for the P11 IC. A statistically significant LET dependence was found only for the P11 IC in pristine beams only with a magnitude of <1.10%. Conclusions: The perturbation and k Q correction factor should be calculated for the specific IC to be used in carbon ion beam reference dosimetry as a function of beam quality.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
A new center for heavy ion research
Progress in cancer therapy with ions heavier than protons, i.e., helium, carbon, oxygen and neon, requires research and development capability. Ion research activity, however, is limited from the absence of U.S. accelerator facilities offering ion beams for therapy – placing the U.S. significantly behind Europe and Asia. With dramatic advances in beam delivery and compact accelerators, the potential exists to create a facility that can play a leadership role in particle therapy and ion-based research. This paper announces summary details of a new center for ion therapy research under construction in Waco, TX, in collaboration with recognized accelerator entities both academic and industrial. The advanced accelerator technologies will produce beams for both clinical and research applications, offering a complete range of ions, intensities and energies required by the medical community, including the capability to perform ultra-high dose irradiation (FLASH) research. FLASH, a recent research initiative, which has the potential of reducing cancer treatment toxicities, is an important if not critical capability for a competitive research center – requiring beam intensities well beyond those provided by current medical accelerators. Building a state-of-the-art cancer research center within a comprehensive facility will provide the resources to promote ion therapy in the U.S, including, preclinical/clinical trials and protocols between modalities, and also support broad ion R&D.
43 PARTICLE ACCELERATORS↗
Compact, Achromatic Non-scaling FFAG Accelerator for HEP, Commercial and Medical Applications (CRADA FRA-2008-0005 Final Report)
Proton and light-ion accelerators have many research and medical applications, but the current state of technology in accelerators severely limits their widespread use: (1) synchrotrons have an intrinsic low duty cycle and become quite large for light ions; and (2) cyclotrons do not have energy variability and require complex superconducting magnets for high energy. A new concept in non-scaling Fixed-Field Alternating-Gradient (FFAGs) has been invented that incorporates both the energy variability of the synchrotron and the high duty cycle of the cyclotron. The concept uses normal-conducting, combined-function magnets that apply only constant (dipole) and linear-gradient (quadrupole) fields to stabilize the accelerator. This project will develop an optimized design for a new non-scaling and cost-effective innovation in FFAG accelerators. The accelerator design will have optics that can stably accelerate protons to 250 MeV (or higher) and carbon ions to =200 MeV, an energy considered ideal for radiation therapy. Phase I will optimize, fully simulate, and demonstrate the feasibility of this accelerator. Commercial Applications and other Benefits as described by the awardee: The fixed-field acceleration concept should eliminate some of the most pronounced technical difficulties, expense, maintenance, and required expertise faced in conventional proton and light-ion accelerators. In addition to the application for high energy physics, these accelerators should have application in cancer treatment, radiopharmaceuticals, and medical isotope production, and materials science.
43 PARTICLE ACCELERATORS↗
Wireless Bioelectronic Modulation of Membrane Potential in Glioblastoma Using Carbon Nanotube Porins
Disruption of membrane potential (V mem ) can activate pathways associated with cancer proliferation. Manipulating ion channels may therefore present an effective strategy for treating cancers that fail to respond to conventional therapies. One approach to target these channels is to manipulate the membrane charge, which involves the use of wireless bipolar electrodes such as carbon nanotube porins (CNTPs) inserted into cell membranes to modulate membrane charge and ionic flux. By utilizing membrane dyes, we observed alterations in V mem induced by CNTPs and externally applied voltages. Analyses of cellular behaviors and processes indicated that V mem is more receptive to stimuli in invasive cancers, while it leads to increased metabolism in less invasive cancers, with notable changes in the cell cycle occurring at approximately 48 h post-treatment in Glioblastoma (GB) cell lines. This work shows that CNTPs, in combination and with externally applied voltages, can modulate V mem and alter cancer cell processes, supporting their potential as a therapeutic.
bioelectricity↗
Tailoring Polymer Colloids Derived Porous Carbon Spheres Based on Specific Chemical Reactions
Porous carbon spheres derived from polymer colloids with regular geometry, monodispersed morphology, well-controlled contents and structures play important roles in many areas of application, such as energy storage/conversion, gas adsorption/separation, catalysis, and chemo-photothermal therapy. Suitable polymerization reaction and synthetic strategy are both critical for the obtainment of stable polymer colloids as carbon precursors. Basic polymerization reactions are the cornerstones of synthetic strategies, which directly provides the direct molecular-based design of functionalized polymer/ carbon spheres. Thus, this progress report mainly focuses on the summary of suitable polymerization reactions for colloidal polymer derived porous carbon spheres. Recent advances in the synthetic strategies and applications are also discussed, including their corresponding polymerization reactions. Finally, the perspectives for the development of polymer derived porous carbon spheres are provided based on the controlled synthesis of polymer colloids and optimization over the carbonization process to achieve highly functionalized carbon spheres for practical applications.
36 MATERIALS SCIENCE↗
Highly Active Carbon–Platinum-Based Nanozymes: Synthesis, Characterization, and Immunoassay Application
Nanozymes (nanomaterials with intrinsic enzyme-like characteristics) have gained much attention for diagnostics and therapy due to their excellent enzyme-mimicking capability, great stability in environments, and facile and low-cost production. However, developing nanozymes with a high catalytic constant, K cat , has been challenging. Herein, we report a class of nanozyme-mimicking peroxidases, which are formed by depositing ultrasmall platinum nanoparticles (Pt NPs) 1–2 nm in size on the surface of hydrophilic nitrogen-doped carbon nanoparticles (CN NPs). These nanozymes defined as CN-Pt NPs show a high peroxidase-like activity with K cat values of 1.27 M·mL/s·g for 3,3,5,5′-tetramethylbenzidine (TMB) and 1.97 M·mL/s·g for hydrogen peroxide (H 2 O 2 ), respectively, which are at least one or two orders higher than many other reported carbon–noble metal-based nanozymes. Our developed CN-Pt NPs were further utilized in a colorimetric immunoassay as signal amplifiers for the biomarker detection of Burkholderia pseudomallei, a Gram-negative bacterial pathogen classified as a tier 1 select agent by the US CDC. In conclusion, the assay achieved lower limits of detection of 0.11 ng/mL in phosphate-buffered saline (PBS) and 0.16 ng/mL in human serum, when compared to many other assays in detecting the same biomarker.
37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
Spread Out Carbon Bragg Peak at NSRL
Charged particles lose energy continuously while traversing non-vacuum medium but have a sharp peak of dE/dx near the end of the path length. This can be very beneficial for cancer radiotherapy where healthy tissues surrounding a tumor are left with little dose compared to traditional therapy methods. However, since the region of high dose is localized to such a small area, it can present challenges when attempting to treat tumors of larger volume. By utilizing a variable thickness degrader system, the treatment area can be expanded during clinical treatment applications. To accommodate these types of radiobiology experiments, NSRL has produced a spread-out Bragg peak degrader wheel which aims to widen the Bragg peak of a 108 MeV/n Carbon beam to deliver a constant linear energy transfer, in water, of 97.7 keV/µm over a range of 36.7 mm.
43 PARTICLE ACCELERATORS↗